Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

Cancer
Karen KellyJames L Gulley

Abstract

Antibodies targeting the programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) checkpoint may cause adverse events (AEs) that are linked to the mechanism of action of this therapeutic class and unique from those observed with conventional chemotherapy. Patients with advanced solid tumors who were enrolled in the phase 1 JAVELIN Solid Tumor (1650 patients) and phase 2 JAVELIN Merkel 200 (88 patients) trials received avelumab, a human anti-PD-L1 IgG1 antibody at a dose of 10 mg/kg every 2 weeks. Treatment-related AEs (TRAEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). In post hoc analyses, immune-related AEs (irAEs) were identified via an expanded AE list and medical review, and infusion-related reactions (IRRs) occurring ≤2 days after infusion and symptoms occurring ≤1 day after infusion and resolving ≤2 days after onset were identified based on prespecified Medical Dictionary for Regulatory Activities (MedDRA) terms. Of the 1738 patients analyzed, grade ≥3 TRAEs occurred in 177 (10.2%); the most common were fatigue (17 patients; 1.0%) and IRR (10 patients; 0.6%). TRAEs led to discontinuation in 107 patients (6.2%) and death in 4 patients (0.2%)...Continue Reading

References

Apr 1, 1980·The Journal of Allergy and Clinical Immunology·S R Hirsch, J H Kalbfleisch
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Mar 31, 2010·Clinical Journal of Oncology Nursing·Wendy H Vogel
May 23, 2012·Clinical & Developmental Immunology·Esdy N RozaliW Joost Lesterhuis
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Sep 6, 2014·Chinese Journal of Cancer·Elad SharonHelen X Chen
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A PostowJedd D Wolchok
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Apr 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberMary L Disis
May 7, 2015·Cancer Immunology Research·Ross StewartMatthew McCourt
May 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikAnthony W Tolcher
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok
Feb 15, 2016·Cancer Treatment Reviews·Lavinia SpainJames Larkin
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe MassardNeil H Segal
Apr 5, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea B ApoloJames L Gulley

❮ Previous
Next ❯

Citations

Aug 4, 2018·Der Nervenarzt·S KnaussM Endres
Nov 28, 2018·Human Vaccines & Immunotherapeutics·Julie M Collins, James L Gulley
Jan 9, 2019·Journal of Cancer Research and Clinical Oncology·Marco GalloUNKNOWN NIKE Group
Mar 14, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·John A ThompsonJillian L Scavone
May 8, 2019·Immunotherapy·Giandomenico RovielloNavid Sobhani
Jul 10, 2019·Expert Opinion on Biological Therapy·Mathieu LarroquetteCharlotte Domblides
Sep 26, 2019·Clinical Pharmacology and Therapeutics·Ana M NovakovicAkash Khandelwal
Mar 25, 2020·International Ophthalmology Clinics·Giancarlo A Garcia, Andrea L Kossler
Apr 19, 2020·Journal for Immunotherapy of Cancer·Patrick BolandSabina Sandigursky
Apr 24, 2020·British Journal of Clinical Pharmacology·Yara AbdouMarc S Ernstoff
May 17, 2019·Nature Reviews. Clinical Oncology·Filipe MartinsMichel Obeid
May 15, 2020·Expert Opinion on Biological Therapy·Viktoria StühlerJens Bedke
Jul 28, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Benoit YouFrancois Golfier
Jun 5, 2018·International Journal of Breast Cancer·Jessica M S JutzySteven J Chmura
May 26, 2018·Targeted Oncology·Matt Shirley
Nov 22, 2019·Expert Opinion on Emerging Drugs·Andrea Muto, Cesare Gridelli
Dec 18, 2018·Frontiers in Oncology·Thijs RoelofsenAnne M van Altena
Feb 21, 2019·American Journal of Clinical Dermatology·Mahtab Samimi
Nov 22, 2020·Journal for Immunotherapy of Cancer·Karen KellyJames L Gulley
Aug 13, 2020·Oncology Reviews·Giuseppe Luigi BannaAlfredo Addeo
Apr 15, 2021·Reviews in Endocrine & Metabolic Disorders·Manuela AlbertelliDiego Ferone
Apr 28, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T K ChoueiriL Albiges
Nov 2, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bryan J SchneiderKathryn Bollin
Dec 31, 2021·Dermatologic Therapy·Loren E HernandezKeyvan Nouri

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01772004
NCT02155647

Software Mentioned

Infante
JAVELIN

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.